Yukiko Nishimura
Overview
Explore the profile of Yukiko Nishimura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
229
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishimura Y, Iizuka D, Takabatake M, Daino K, Nishimura M, Morioka T, et al.
Anticancer Res
. 2024 Sep;
44(10):4261-4272.
PMID: 39348980
Background/aim: Breast cancer is a heterogeneous disease with many subtypes, and the association between these subtypes and exposure to environmental factors such as radiation remains controversial. Although the rat is...
2.
Jonker A, Cavaller-Bellaubi M, Nishimura Y, Pearce D
Lancet Glob Health
. 2024 Sep;
12(10):e1587.
PMID: 39304232
No abstract available.
3.
Hamoya T, Kaminaga K, Igarashi R, Nishimura Y, Yanagihara H, Morioka T, et al.
Nanoscale Horiz
. 2024 Sep;
9(11):1938-1947.
PMID: 39297440
Quantum sensing using the fluorescent nanodiamond (FND) nitrogen-vacancy center enables physical/chemical measurements of the microenvironment, although application of such measurements in living mammals poses significant challenges due to the unknown...
4.
Nagata K, Nishimura M, Daino K, Nishimura Y, Hattori Y, Watanabe R, et al.
J Radiat Res
. 2024 Sep;
65(5):640-650.
PMID: 39238338
Ionizing radiation promotes mammary carcinogenesis. Induction of DNA double-strand breaks (DSBs) is the initial event after radiation exposure, which can potentially lead to carcinogenesis, but the dynamics of DSB induction...
5.
Shimizu H, Nishimura Y, Shiide Y, Akimoto M, Yashiro M, Ueda M, et al.
Clin Ther
. 2023 Nov;
45(12):1251-1258.
PMID: 37953075
Purpose: Edaravone is a neuroprotective agent approved as an intravenous treatment for amyotrophic lateral sclerosis (ALS). The intravenous administration of edaravone places a burden on patients and there is a...
6.
Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants
Shimizu H, Nishimura Y, Shiide Y, Akimoto M, Matsuda H, Kato Y, et al.
Clin Ther
. 2022 Nov;
44(12):1552-1565.
PMID: 36376130
Purpose: The safety and efficacy of intravenous edaravone, a neuroprotectant used for the treatment of amyotrophic lateral sclerosis (ALS), have been shown in clinical trials. An oral suspension of edaravone...
7.
Shimizu H, Nishimura Y, Shiide Y, Ueda M, Yokota S, Kato Y, et al.
Clin Pharmacol Drug Dev
. 2022 Oct;
12(1):77-84.
PMID: 36225132
Intravenous edaravone is used to treat patients with amyotrophic lateral sclerosis. This randomized, open-label, two-way crossover, single-dose phase 1 study compared the relative bioavailability of a newly developed edaravone oral...
8.
Imaoka T, Nishimura M, Daino K, Hosoki A, Kudo K, Iizuka D, et al.
Radiat Prot Dosimetry
. 2022 Sep;
198(13-15):1036-1046.
PMID: 36083756
The uncertain cancer risk of protracted radiation exposure at low dose rates is an important issue in radiological protection. Tissue stem/progenitor cells are a supposed origin of cancer and may...
9.
Nakamura Y, Kubota J, Nishimura Y, Nagata K, Nishimura M, Daino K, et al.
Cancer Sci
. 2022 Jul;
113(10):3362-3375.
PMID: 35851737
Women who are heterozygous for deleterious BRCA1 germline mutations harbor a high risk of hereditary breast cancer. Previous Brca1-heterozygous animal models do not recapitulate the breast cancer phenotype, and thus...
10.
Nishimura M, Imaoka T, Daino K, Nishimura Y, Kokubo T, Takabatake M, et al.
Anticancer Res
. 2022 Apr;
42(5):2415-2423.
PMID: 35489722
Background/aim: Genetic and environmental factors interact to dictate the risk of cancer, and animal models are expected to provide avenues for identifying such interactions. The aim of the study was...